Generic Name and Formulations:
Oxybutynin 3.9mg/day; transdermal patch.
Indications for OXYTROL:
Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Apply to clean, dry area on the abdomen, hip, or buttock. 1 patch twice weekly (every 3–4 days). Rotate application sites.
Urinary or gastric retention, uncontrolled narrow-angle glaucoma; or patients at risk for these.
Bladder outflow or GI obstruction. Hepatic or renal impairment. Ulcerative colitis. Intestinal atony. Hiatus hernia/GERD. Discontinue if skin hypersensitivity or angioedema develops; consider discontinuing if anticholinergic CNS effects occur. Avoid in myasthenia gravis; discontinue if symptoms occur. Exposure to high environmental temperature. Pregnancy. Nursing mothers.
CNS depression potentiated by alcohol, other CNS depressants. Additive effects with other anticholinergics. May affect GI absorption of other drugs. Caution with drugs that cause or exacerbate esophagitis (eg, bisphosphonates).
Local reactions, anticholinergic effects (eg, dry mouth, constipation, dizziness, abnormal vision, somnolence, confusion, hallucinations), headache, diarrhea, rash.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Improving the Care of Aging Adults Living With HIV
- Infection Prevention Differs Between Small, Large Hospitals
- International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention
- Previous Missed Appointments Predict Likelihood of Trend in Patients With HIV
- FDA Warns Against Long-Term Azithromycin Use for Some
- Identifying the Source of C difficile in Hospitalized Patients
- Antibiotics Often Unnecessary for Sacral Pressure Ulcers Complicated by Osteomyelitis
- Sensitivity and Specificity of 7 Treponemal Tests for Syphilis Diagnosis
- Automated EHR Algorithm More Effective Than Nurse-Driven Protocol for HCV, HIV Screening
- A Pan-Tuberculosis Regimen: The Debate Continues
- HCV Eradication in HIV/HCV-Coinfection Decreases Immune Activation
- Tolerability of Switching to Long-acting Cabotegravir Plus Rilpivirine From Current HIV-1 Regimen
- Time to Blood Culture Positivity Predictive of Mortality in S Aureus Infective Endocarditis
- C difficile Tied to Increased Graft Loss in Solid Organ Recipients
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd